Skip to main content
. Author manuscript; available in PMC: 2023 Jan 23.
Published in final edited form as: Cell Metab. 2022 Feb 1;34(2):193–196. doi: 10.1016/j.cmet.2022.01.002

Figure 1. Current and potential stem cell-based therapeutic strategies for T1D treatment.

Figure 1.

Transplantation of pancreatic endoderm cells (PECs) and stem cell-derived beta-like cells into preclinical animal models has demonstrated the ability to successfully reverse diabetes, albeit with caveats associated with each approach. Recently, results from a multi-center clinical trial (NCT03163511) provided preliminary results showing the feasibility of using encapsulated stem cell-derived PECs as replacement therapy for patients suffering from T1D. A combined phase 1/2 clinical trial (NCT04786262) is also ongoing and awaits dissemination of peer-reviewed results.